HIV/AIDS Year in Review 2011

Home>
Specialties>
HIV/AIDS Clinical Care>
Letter to Readers

HIV/AIDS Year in Review 2011

Our physician-editors offer their perspective on the year's most important stories in HIV medicine.

For HIV specialists, notable memories of 2011 will undoubtedly include the presentation and publication of the landmark HPTN 052 study, which proved, finally, that the divide between HIV treatment and prevention is a false one. The repercussions of this study are vast — both in the clinic, where patients almost universally acknowledge that these findings motivate them to want therapy, and in policy forums, where leaders now need to consider whether to recommend HIV treatment for all patients, regardless of CD4-cell count. In our 2011 Year in Review, we offer our perspective on this and other important themes in HIV clinical practice today.

HIV Treatment as Prevention — The Time Is Now

Antiretroviral Pre-Exposure Prophylaxis: New Hope and New Conundrums

Economic Factors Hamper HIV Control Efforts

Clarity on When to Start ART in Active TB

New HCV Treatments Look Promising for HIV/HCV-Coinfected Patients

HIV Continues to Target Young Black MSM . . .

Cure: No Longer a Four-Letter Word in HIV Research

When to Start ART in Asymptomatic Patients

Growing the Integrase Inhibitor Class — Elvitegravir and Dolutegravir

Rilpivirine Arrives — with Caveats

NRTI-Sparing Regimens Continue to Disappoint

— Paul E. Sax, MD

Published in Journal Watch HIV/AIDS Clinical Care December 30, 2011

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Remark subject:*

Your remark:*

Fields marked with an * are required.

Name as you'd like it to appear:
First & middle initial:*

Last:*

Email address (will not
be published):*

Professional specialty:*

Place of work (optional):

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

No competing interests

Or, the following competing interests (for example, financial stakes or professional relationships):

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.